Bristol-Myers Squibb Company (BMY) Hits New 12-Month High at $62.96
Bristol-Myers Squibb Company (NYSE:BMY) reached a new 52-week high during trading on Thursday . The stock traded as high as $62.96 and last traded at $62.90, with a volume of 9,537,469 shares traded. The stock had previously closed at $59.87.
Several research firms have recently commented on BMY. Credit Suisse Group set a $58.00 target price on shares of Bristol-Myers Squibb and gave the stock a “hold” rating in a research report on Wednesday, August 16th. BMO Capital Markets reaffirmed an “underperform” rating and issued a $47.00 target price (down from $51.00) on shares of Bristol-Myers Squibb in a research report on Wednesday, July 26th. Leerink Swann dropped their target price on shares of Bristol-Myers Squibb from $66.00 to $61.00 and set an “outperform” rating for the company in a research report on Friday, July 28th. Goldman Sachs Group, Inc. (The) reaffirmed a “buy” rating and issued a $63.00 target price on shares of Bristol-Myers Squibb in a research report on Wednesday, August 9th. Finally, Vetr raised shares of Bristol-Myers Squibb from a “buy” rating to a “strong-buy” rating and set a $64.33 target price for the company in a research report on Wednesday, July 26th. One equities research analyst has rated the stock with a sell rating, nine have issued a hold rating and eleven have issued a buy rating to the stock. The stock has a consensus rating of “Hold” and an average price target of $62.42.
The stock has a 50-day moving average of $57.10 and a 200 day moving average of $55.60. The stock has a market capitalization of $103.25 billion, a price-to-earnings ratio of 22.99 and a beta of 1.18.
Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings results on Thursday, July 27th. The biopharmaceutical company reported $0.74 earnings per share for the quarter, topping analysts’ consensus estimates of $0.73 by $0.01. Bristol-Myers Squibb had a return on equity of 32.33% and a net margin of 22.66%. The company had revenue of $5.14 billion during the quarter, compared to analysts’ expectations of $5.09 billion. During the same quarter in the previous year, the firm earned $0.69 earnings per share. The business’s quarterly revenue was up 5.6% compared to the same quarter last year. Equities analysts predict that Bristol-Myers Squibb Company will post $2.98 EPS for the current fiscal year.
In related news, Director Theodore R. Samuels II purchased 6,000 shares of Bristol-Myers Squibb stock in a transaction on Wednesday, August 2nd. The stock was bought at an average price of $55.94 per share, with a total value of $335,640.00. Following the completion of the transaction, the director now directly owns 18,000 shares of the company’s stock, valued at $1,006,920. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. 0.23% of the stock is owned by insiders.
Large investors have recently made changes to their positions in the business. American National Bank lifted its position in shares of Bristol-Myers Squibb by 36.0% during the 1st quarter. American National Bank now owns 1,919 shares of the biopharmaceutical company’s stock worth $104,000 after purchasing an additional 508 shares during the last quarter. Tradewinds Capital Management LLC lifted its position in shares of Bristol-Myers Squibb by 34.6% during the 2nd quarter. Tradewinds Capital Management LLC now owns 1,945 shares of the biopharmaceutical company’s stock worth $108,000 after purchasing an additional 500 shares during the last quarter. Atlantic Trust LLC acquired a new position in shares of Bristol-Myers Squibb during the 2nd quarter worth about $111,000. Welch Investments LLC lifted its position in shares of Bristol-Myers Squibb by 3.9% during the 1st quarter. Welch Investments LLC now owns 2,109 shares of the biopharmaceutical company’s stock worth $115,000 after purchasing an additional 79 shares during the last quarter. Finally, Crestwood Advisors Group LLC acquired a new position in shares of Bristol-Myers Squibb during the 1st quarter worth about $116,000. 68.80% of the stock is owned by institutional investors.
Bristol-Myers Squibb Company Profile
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.